Sancilio sold certain assets to Micelle Biopharma
- Background: Sancilio Pharmaceuticals Company, Inc. (“Sancilio”), based in Riviera Beach, FL, is an integrated specialty pharmaceutical company that develops, manufactures, and commercializes pharmaceutical products, over-the-counter and behind-the-counter products, and dietary supplements in the dental and women’s health markets.
- Cassel Salpeter:
-
- Served as financial advisor to the Company
- Ran a competitive sales process, identifying and contacting over 300 strategic and financial parties
- Provided assistance throughout all phases of the Chapter 11 Section 363 sales process, due diligence, and auction
-
- Challenges:
-
- Expedited sales timeline with less than six weeks to identify and solicit interest from potential bidders
- Simultaneous, multiple sales processes for different divisions of the Company
-
- Outcome: On August 8, 2018, Altemia and the ALT Platform, a Phase III ready product for the treatment of sickle cell disease; a prenatal and dental portfolio of prenatal vitamins and fluorides; and the plant and labs of Sancilio Pharmaceuticals Company, Inc., were purchased by Micelle Biopharma, Inc.
